Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment.

The Journal of biological chemistry - 1 Dec 2022

Donahue Kristine, Xie Haibo, Li Miyang, Gao Ang, Ma Min, Wang Yidan, Tipton Rose, Semanik Nicole, Primeau Tina, Li Shunqiang, Li Lingjun, Tang Weiping, Xu Wei

Abstract excerpt

HSP90 inhibitors can target many oncoproteins simultaneously, but none have made it through clinical trials due to dose-limiting toxicity and induction of heat shock response, leading to clinical resistance. We identified diptoindonesin G (dip G) as an HSP90 modulator that can promote degradation of HSP90 clients by binding to the middle domain of HSP90 (Kd = 0.13 ± 0.02 μM) without inducing heat shock response....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzofurans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cell Proliferation

Share to HSP90 Heat-Shock Proteins

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36395883
DOI: 10.1016/j.jbc.2022.102700
PMCID: PMC9771721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment.PMID 36395883Read ↗

Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis.Semantic proximity Read ↗

HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insightsSemantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.Semantic proximity Read ↗

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor modelsSemantic proximity Read ↗

Hsp90: A Global Regulator of the Genotype-to-Phenotype Map in Cancers.Semantic proximity Read ↗

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancerSemantic proximity Read ↗

N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.Semantic proximity Read ↗

Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.